USA

(74) Agent or Attorney TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS

(56) References

Cited: WO-A1-2009/026558, H. Attarwala: "TGN1412: From Discovery to Disaster", Journal of young pharmacists, vol.2, no.3, 1 July 2010 (2010-07-01), pages 332-336, XP055407473, India ISSN: 0975-1483, DOI: 10.4103/0975-1483.66810, WO-A1-2012/054438, WO-A2-2009/055783, WO-A2-2010/029513, WO-A2-2012/064792, Amgen: "Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 145 in Subjects With Hyperlipidemia on Stable Doses of a Statin", , 27 May 2010 (2010-05-27), XP002682099, Retrieved from the Internet: URL:http://clinicaltrials.gov/ct2/show/NCT 01133522?term=amg+145&rank=2 [retrieved on 2012-08-21], SOUTAR ANNE K: "Unexpected roles for PCSK9 in lipid metabolism.", CURRENT OPINION IN LIPIDOLOGY JUN 2011 LNKD-PUBMED:21494143, vol.22, no.3, June 2011 (2011-06), pages 192-196, XP008155160, ISSN: 1473-6535, pfizer: "Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia", , 3 November 2010 (2010-11-03), XP002682100, Retrieved from the Internet: URL:http://clinicaltrials.gov/ct2/show?ter m=rn316&rank=2 [retrieved on 2012-08-21], CHAN JOYCE C Y ET AL: "A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol.106, no.24, 16 June 2009 (2009-06-16), pages 9820-9825, XP002570200, ISSN: 0027-8424, DOI: 10.1073/PNAS.0903849106, WINTER G ET AL: "Humanized antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol.14, no.6, 1 January 1993 (1993-01-01), pages 243-246, XP002357357, ISSN: 0167-5699, DOI: 10.1016/0167-5699(93)90039-N, BENDIG M M ED - GORDANA VUNJAK-NOVAKOVIC:

"HUMANIZATION OF RODENT MONOCLONAL ANTIBODIES BY CDR GRAFTING", METHODS, ACADEMIC PRESS, US, vol.8, 1 January 1995 (1995-01-01), pages 83-93, XP002943667, ISSN: 1046-2023, Summary of product characteristics - Praluent, Highlight of prescribing information - Praluent, ANROOPB NAIR ET AL: "A simple practice guide for dose conversion between animals and human", JOURNAL OF BASIC AND CLINICAL PHARMACY, vol.7, no.2, 1 January 2016 (2016-01-01) , page 27, XP055407475, India ISSN: 0976-0105, DOI: 10.4103/0976-0105.177703, U S: "Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)", FDA JOURNAL, 1 July 2005 (2005-07-01), XP055152598,, WO-A1-2010/077854

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/